Synthon says glatiramer shows equivalence to Teva's Copaxone Synthon announced that the companyís glatiramer acetate met the main endpoint of a late-stage study in patients with relapsing remitting multiple sclerosis. The Phase III Glatiramer Acetate clinical trial to assess equivalence with Teva's (TEVA) Copaxone is to-date the only Phase III study conducted with a generic version of Copaxone and has demonstrated an equivalent efficacy and safety profile for Synthonís glatiramer acetate compared to Copaxone, Synthon said. Synthon has already submitted an Abbreviated New Drug Application for glatiramer acetate for injection in pre-filled syringes to the FDA in November 2011.
Senate Health, Education, Labor & Pensions Committee to hold a hearing The Subcommittee on Primary Health and Aging holds a hearing entitled, "Why Are Some Generic Drugs Skyrocketing In Price?" with President & CEO Vigodman of Teva Pharmaceutical and President & CEO Bedrosian of Lannett Company on November 20 at 1 pm. Webcast Link
Teva patent victory over Warner Chilcott, Roche affirmed The U.S. Court of Appeals for the Federal Circuit ruled that a district court was correct to grant summary judgment to Teva (TEVA) in a patent dispute with Warner Chilcott and Roche (RHHBY) over patents related to osteoporosis drug risedronate.
Teva calls active on renewed takeover chatter Teva November 57 and 58 calls are active on total call volume of 21K contracts (2K puts) following renewed takeover chatter. November call option implied volatility is at 18, December is at 19; compared to its 26-week average of 24 according to Track Data. Active call volume suggests traders taking positions for upside price movement.